HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.

AuthorsHugh A Sampson, Donald Y M Leung, A Wesley Burks, Gideon Lack, Sami L Bahna, Stacie M Jones, Dennis A Wong
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 127 Issue 5 Pg. 1309-10.e1 (May 2011) ISSN: 1097-6825 [Electronic] United States
PMID21397314 (Publication Type: Clinical Trial, Phase II, Letter, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Allergens
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Plant Proteins
  • Omalizumab
Topics
  • Administration, Oral
  • Adolescent
  • Adult
  • Allergens (administration & dosage)
  • Antibodies, Anti-Idiotypic (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, immunology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Arachis (immunology)
  • Child
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omalizumab
  • Peanut Hypersensitivity (immunology, therapy)
  • Plant Proteins (administration & dosage, immunology)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: